Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
5(56%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
6
67%
Ph phase_3
1
11%
Ph early_phase_1
1
11%
Ph phase_2
1
11%

Phase Distribution

7

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
6(66.7%)
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

9

all time

Status Distribution
Active(6)
Completed(3)

Detailed Status

Recruiting4
Completed3
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (11.1%)
Phase 16 (66.7%)
Phase 21 (11.1%)
Phase 31 (11.1%)

Trials by Status

active_not_recruiting111%
not_yet_recruiting111%
completed333%
recruiting444%

Recent Activity

5 active trials
Showing 5 of 9
not_yet_recruitingearly_phase_1

Pilot Study of Casdatifan-Treated Refractory Renal Cell Carcinoma

NCT07748988
active_not_recruitingphase_1

A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

NCT07000149
recruitingphase_3

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT07011719
recruitingphase_1

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

NCT05536141
recruitingphase_1

A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants

NCT07641881
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07748988Early Phase 1

Pilot Study of Casdatifan-Treated Refractory Renal Cell Carcinoma

Not Yet Recruiting
NCT07000149Phase 1

A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

Active Not Recruiting
NCT07011719Phase 3

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Recruiting
NCT05536141Phase 1

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Recruiting
NCT07641881Phase 1

A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants

Recruiting
NCT07397611Phase 2

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Recruiting
NCT06919991Phase 1

Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)

Completed
NCT05999513Phase 1

A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers

Completed
NCT05117554Phase 1

Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9